The Mid-Ohio Valley Parkinson’s Support Group’s Parkinson’s and Movement Disorder Symposium is an educational event for those ...

The celebrity interview has undergone a radical transformation. The format once defined by Diane Sawyer’s sober, couch-bound ...

By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

VALBY, Denmark, Oct. 2, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of ...

HONOLULU, Oct. 5, 2025 /PRNewswire/ -- An orally administered drug to redistribute excess iron and lower cellular oxidative stress was found to slow disease progression of multiple system atrophy (MSA ...

Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and ...

Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –MELBOURNE, Australia and SAN ...